Glecaprevir Hep C Treatments

Glecaprevir Hep C Treatments

One form of treatment for the hepatitis C (Hep C) virus is a combination of glecaprevir and pibrentasvir, also known as Mavyret. Glecaprevir hep C treatments were approved by the US Food and Drug Administration (FDA) in 2017 for the virus genotypes one to six in adults. Patients with kidney disease, those with mild cirrhosis, and patients without liver disease are able to use this treatment.

Glecaprevir Hep C Treatments

This glecaprevir treatment is the first treatment that is meant for all hep C patients and is about 8, 12 or 16 weeks in duration.

A clinical trial involving approximately 2,300 patients with either one of the six hep C genotypes showed that nearly 92% to 100% of the patients had no signs of the hep C virus 12 weeks after their treatment had been completed.

All patients took the treatment for either 8, 12 or 16 weeks. The length of your treatment may depend on your genotype, current medical condition, the severity of your case of hep C, and previous treatment history.

Side Effects of Glecaprevir Hep C Treatments

Some of the most common side effects that occurred as a result of the glecaprevir and pibrentasvir in the study were nausea, headaches, and fatigue.

Do not use this treatment if you have had the hepatitis B virus, as this may cause a reactivation of the virus. Also, do not use Mavyret if you have moderate to severe cirrhosis or if you are taking any other medication that contains atazanavir and rifampin.

According to the FDA, nearly 2.7 to 3.9 million Americans suffer from hep C. Be sure to talk with your doctor before you decide to take any medication that you may be considering to treat your case of hep C. Together, you and your doctor will be able to determine if this treatment of glecaprevir will provide the best results regarding your condition.

Remember to take any medications as directed by your doctor or a healthcare professional.

Featured Image: DepositPhotos/ tashatuvango